Prospectus excerpt:  Peregrine Pharmaceuticals, Inc. is offering 700,000 shares of our 10.50% Series E Convertible Preferred Stock, which we refer to in this prospectus supplement as the Series E Preferred Stock. This is an original issuance of the Series E Preferred Stock. We are also registering up to 20,300,000 shares of our common stock, par value $0.001 per share, which we refer to as common stock in this prospectus supplement (up to 23,345,000 shares of our common stock assuming exercise in full of the overallotment option described below). Such shares of common stock may be issued as a result of the conversion of the Series E Preferred Stock as more fully described herein. Our common stock is currently listed on The NASDAQ Capital Market, or NASDAQ, under the symbol ÙPPHM.ˆ We will bear all costs associated with the offering.